Alzheimer's disease modifying compounds

AfaSci has developed novel tricyclic pyrone compounds CP2 and TP70 in collaboration with Kansas State University and UC Davis. These compounds have new mechanisms of action potentially for the treatment of Alzheimer's disease, with the following features:
  • High oral bioavailability
  • Excellent blood–brain barrier permeability
  • Low neurotoxicity

Oral administration of these compounds to transgenic models of Alzheimer's disease has demonstrated reduced soluble and insoluble Aβ species in the brain, as well as preserved memory and motor function. At the cellular level, they restored axonal trafficking and increased cellular cholesterol efflux. Last, CP2 causes activity-dependent inhibition of NMDA receptors-mediated synaptic neurotransmission, while TP70 enhanced hippocampal synaptic plasticity (e.g., long-term potentiation).

Furthermore, both leads also decreased glucose in a high-fat-diet induced diabetic model in mice.

Status: IND candidates ready for IND-enabling studies